Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait ...

M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. | M+C Saatchi North ...

Amgen has acquired U.K.-based biotechnology company Dark Blue Therapeutics in a transaction valued at up to $840 million. Amgen on Tuesday said the deal adds an investigational small molecule that ...

With no new safety signals emerging in its phase 3 trials, Alumis plans to file for FDA approval in the back half of 2026.

SAN FRANCISCO -- Including encorafenib (Braftovi) and cetuximab (Erbitux) in the first-line treatment of BRAF V600E-mutated ...

This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...

Aktis Oncology is aiming to bring in $182 million—or more—from what looks set to be the first biotech IPO of 2026. | Aktis ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

The global amyloidosis treatment market is on a trajectory of significant expansion, driven by heightened disease awareness, ...